NCT07150091 - Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

April 17, 2025

Study Completion Date

March 11, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered.

DRUG

Nirogacestat

Nirogacestat will be administered.

DRUG

Lenalidomide

Lenalidomide will be administered.

DRUG

Dexamethasone

Dexamethasone will be administered.

Trial Locations (12)

11528

GSK Investigational Site, Athens

22083

GSK Investigational Site, Hamburg

44033

GSK Investigational Site, Ulsan

94805

GSK Investigational Site, Villejuif

02215

GSK Investigational Site, Boston

41253-190

GSK Investigational Site, Salvador

04537-080

GSK Investigational Site, São Paulo

B3H 1V7

GSK Investigational Site, Halifax

01330

GSK Investigational Site, Mexico City

03080

GSK Investigational Site, Seoul

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul